144 related articles for article (PubMed ID: 36226635)
21. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
22. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
23. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer.
Wang X; Zhu J; Li Z; Wei T
PLoS One; 2020; 15(6):e0234843. PubMed ID: 32542018
[TBL] [Abstract][Full Text] [Related]
24. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
25. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
[TBL] [Abstract][Full Text] [Related]
26. Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma.
Li G; Chen W; Gong Y; Wei T; Gong R; Zhu J; Li Z; Lei J
J Pers Med; 2022 Dec; 12(12):. PubMed ID: 36556238
[TBL] [Abstract][Full Text] [Related]
27. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
28. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
29. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy.
Qiu ZL; Shen CT; Luo QY
Thyroid; 2015 Feb; 25(2):229-37. PubMed ID: 25331724
[TBL] [Abstract][Full Text] [Related]
30. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
31. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
32. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
[No Abstract] [Full Text] [Related]
34. Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma.
Maciel J; Cavaco D; Silvestre C; Simões Pereira J; Vilar H; Leite V
Clin Endocrinol (Oxf); 2022 Dec; 97(6):814-821. PubMed ID: 35192239
[TBL] [Abstract][Full Text] [Related]
35. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
[TBL] [Abstract][Full Text] [Related]
36. Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features.
Lorusso L; Minaldi E; Esposito G; Piaggi P; Bottici V; Brogioni S; Giani C; Valerio L; Molinaro E; Elisei R; Agate L
J Endocrinol Invest; 2023 Oct; 46(10):2165-2173. PubMed ID: 37084131
[TBL] [Abstract][Full Text] [Related]
37. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.
Wenter V; Jellinek A; Unterrainer M; Ahmaddy F; Lehner S; Albert NL; Bartenstein P; Knösel T; Spitzweg C; Ilhan H; Todica A
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2526-2535. PubMed ID: 31410542
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
[TBL] [Abstract][Full Text] [Related]
40. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Willis AI
Surg Oncol; 2019 Jun; 29():184-189. PubMed ID: 31196486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
